Search Results - "Park, Youn C."

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer by Smith, Matthew R, Saad, Fred, Chowdhury, Simon, Oudard, Stéphane, Hadaschik, Boris A, Graff, Julie N, Olmos, David, Mainwaring, Paul N, Lee, Ji Youl, Uemura, Hiroji, Lopez-Gitlitz, Angela, Trudel, Géralyn C, Espina, Byron M, Shu, Youyi, Park, Youn C, Rackoff, Wayne R, Yu, Margaret K, Small, Eric J

“…Among men with nonmetastatic prostate cancer who had a rapid PSA doubling time and were receiving androgen-deprivation therapy, the median metastasis-free…”
Get full text

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302) by Rathkopf, Dana E, Smith, Matthew R, de Bono, Johann S, Logothetis, Christopher J, Shore, Neal D, de Souza, Paul, Fizazi, Karim, Mulders, Peter F.A, Mainwaring, Paul, Hainsworth, John D, Beer, Tomasz M, North, Scott, Fradet, Yves, Van Poppel, Hendrik, Carles, Joan, Flaig, Thomas W, Efstathiou, Eleni, Yu, Evan Y, Higano, Celestia S, Taplin, Mary-Ellen, Griffin, Thomas W, Todd, Mary B, Yu, Margaret K, Park, Youn C, Kheoh, Thian, Small, Eric J, Scher, Howard I, Molina, Arturo, Ryan, Charles J, Saad, Fred

“…Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic…”
Get full text

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules by DEMETRI, George D, CHAWLA, Sant P, LEBEDINSKY, Claudia, ELSAYED, Yusri A, IZQUIERDO, Miguel A, GOMEZ, Javier, PARK, Youn C, LE CESNE, Axel, VON MEHREN, Margaret, RITCH, Paul, BAKER, Laurence H, BLAY, Jean Y, HANDE, Kenneth R, KEOHAN, Mary L, SAMUELS, Brian L, SCHUETZE, Scott

“…To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic…”
Get full text

Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients by Xu, Xu S, Ryan, Charles J, Stuyckens, Kim, Smith, Matthew R, Saad, Fred, Griffin, Thomas W, Park, Youn C, Yu, Margaret K, Vermeulen, An, Poggesi, Italo, Nandy, Partha

“…We constructed a biomarker-survival modeling framework to explore the relationship between prostate-specific antigen (PSA) kinetics and overall survival (OS)…”
Get full text

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis by Monk, Bradley J, Herzog, Thomas J, Kaye, Stanley B, Krasner, Carolyn N, Vermorken, Jan B, Muggia, Franco M, Pujade-Lauraine, Eric, Park, Youn C, Parekh, Trilok V, Poveda, Andres M

“…Abstract Aim Trabectedin in combination with pegylated liposomal doxorubicin (PLD) improves progression-free survival (PFS) compared to PLD alone in recurrent…”
Get full text

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer by Fizazi, Karim, Tran, NamPhuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez-Antolin, Alfredo, Alekseev, Boris Y, Özgüroğlu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C, Todd, Mary B, Chi, Kim N

“…The addition of abiraterone, a drug that blocks endogenous androgen synthesis, to standard androgen-deprivation therapy in patients with newly diagnosed,…”
Get full text

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis by Lebedinsky, Claudia, Gómez, Javier, Park, Youn C., Nieto, Antonio, Soto-Matos, Arturo, Parekh, Trilok, Alfaro, Vicente, Roy, Elena, Lardelli, Pilar, Kahatt, Carmen

“…Purpose This analysis provides a cross-study evaluation of the cardiac safety of trabectedin. Methods Drug-related cardiac adverse events (CAEs) were retrieved…”
Get full text

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study by Ryan, Charles J, Prof, Smith, Matthew R, Prof, Fizazi, Karim, Prof, Saad, Fred, Prof, Mulders, Peter F A, Prof, Sternberg, Cora N, MD, Miller, Kurt, Prof, Logothetis, Christopher J, Prof, Shore, Neal D, MD, Small, Eric J, Prof, Carles, Joan, MD, Flaig, Thomas W, MD, Taplin, Mary-Ellen, MD, Higano, Celestia S, Prof, de Souza, Paul, Prof, de Bono, Johann S, Prof, Griffin, Thomas W, MD, De Porre, Peter, MD, Yu, Margaret K, MD, Park, Youn C, PhD, Li, Jinhui, PhD, Kheoh, Thian, PhD, Naini, Vahid, PharmD, Molina, Arturo, MD, Rathkopf, Dana E, MD

“…Summary Background Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in…”
Get full text

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer by Fizazi, Karim, Tran, NamPhuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez-Antolin, Alfredo, Alekseev, Boris Y., Özgüroğlu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C., Todd, Mary B., Chi, Kim N.

Get full text

Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer by Xu, Xu Steven, Ryan, Charles J., Stuyckens, Kim, Smith, Matthew R., Saad, Fred, Griffin, Thomas W., Park, Youn C., Yu, Margaret K., De Porre, Peter, Vermeulen, An, Poggesi, Italo, Nandy, Partha

“…Background and Objectives Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic…”
Get full text

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older by Harousseau, Jean-Luc, Martinelli, Giovanni, Jedrzejczak, Wieslaw W., Brandwein, Joseph M., Bordessoule, Dominique, Masszi, Tamas, Ossenkoppele, Gert J., Alexeeva, Julia A., Beutel, Gernot, Maertens, Johan, Vidriales, Maria-Belen, Dombret, Hervé, Thomas, Xavier, Burnett, Alan K., Robak, Tadeusz, Khuageva, Nuriet K., Golenkov, Anatoly K., Tothova, Elena, Mollgard, Lars, Park, Youn C., Bessems, Annick, De Porre, Peter, Howes, Angela J.

“…This phase 3, multicenter, open-label study evaluated the efficacy and safety of tipifarnib compared with best supportive care (BSC), including hydroxyurea, as…”
Get full text

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial by Calvo, Emiliano, Azaro, Analia, Rodon, Jordi, Dirix, Luc, Huizing, Manon, Senecal, Francis Mark, LoRusso, Patricia, Yee, Lorrin, Poggesi, Italo, de Jong, Jan, Triantos, Spyros, Park, Youn C., Knoblauch, Roland E., Parekh, Trilok V., Demetri, George D., von Mehren, Margaret

“…Summary Purpose Trabectedin is metabolized by the liver and has been associated with transient, noncumulative transaminase elevation. Two recent studies…”
Get full text

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy by Johnston, Stephen R. D., Semiglazov, Vladimir F., Manikhas, George M., Spaeth, Dominique, Romieu, Gilles, Dodwell, David J., Wardley, Andrew M., Neven, Patrick, Bessems, Annick, Park, Youn C., De Porre, Peter M., Perez Ruixo, Juan J., Howes, Angela J.

“…Background This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast…”
Get full text

Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: A controlled, randomized, double-blind, multicenter clinical trial by Abraham, Edward, Baughman, Robert, Fletcher, Eugene, Heard, Stephen, Lamberti, James, Levy, Howard, Nelson, Loren, Rumbak, Mark, Steingrub, Jay, Taylor, James, Park, Youn C, Hynds, Jeri Matera, Freitag, Jeffrey

“…OBJECTIVETo evaluate the safety and efficacy of an intravenous liposomal dispersion of prostaglandin E1 as TLC C-53 in the treatment of patients with acute…”
Get full text

Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial by Fizazi, Karim, Feyerabend, Susan, Matsubara, Nobuaki, Ozguroglu, Mustafa, Fein, Luis Enrique, Rodríguez Antolín, Alfredo, Alekseev, Boris Yakovlevich, Sulur, Giri, Protheroe, Andrew, De Porre, Peter, Li, Susan, Park, Youn C., Mundle, Suneel, Tran, Namphuong, Chi, Kim N.

“…Abstract only…”
Get full text

Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial by Chi, Kim N., Tran, Namphuong, Feyerabend, Susan, Matsubara, Nobuaki, Ozguroglu, Mustafa, Fein, Luis Enrique, Rodríguez Antolín, Alfredo, Alekseev, Boris Yakovlevich, Sulur, Giri, Protheroe, Andrew, De Porre, Peter, Li, Susan, Park, Youn C., Mundle, Suneel, Fizazi, Karim

“…Abstract only…”
Get full text

LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer by Fizazi, Karim, Tran, Namphuong, Fein, Luis Enrique, Matsubara, Nobuaki, Rodríguez Antolín, Alfredo, Alekseev, Boris Y., Ozguroglu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C., Todd, Mary Beth, Chi, Kim N.

“…Abstract only LBA3 Background: Pts with newly diagnosed mHNPC, particularly with high-risk characteristics, have a poor prognosis. ADT+docetaxel showed…”
Get full text

LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer by Fizazi, Karim, Tran, Namphuong, Fein, Luis Enrique, Matsubara, Nobuaki, Rodríguez Antolín, Alfredo, Alekseev, Boris Y., Ozguroglu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C., Todd, Mary Beth, Chi, Kim N.

“…Abstract only LBA3 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Saturday, June 3, 2017, and in the Annual…”
Get full text

SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) by Small, Eric Jay, Saad, Fred, Chowdhury, Simon, Hadaschik, Boris A., Graff, Julie Nicole, Olmos, David, Mainwaring, Paul N., Uemura, Hiroji, Lopez-Gitlitz, Angela, Trudel, Geralyn Carol, Espina, Byron M., Shu, Youyi, Park, Youn C., Rackoff, Wayne R., Yu, Margaret K., Smith, Matthew Raymond

“…Abstract only 161 Background: Pts with nmCRPC are at risk for developing metastatic disease and cancer-specific mortality. There are no approved treatments for…”
Get full text

Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial by Fizazi, Karim, Tran, Namphuong, Fein, Luis Enrique, Matsubara, Nobuaki, Bjartell, Anders, Galli, Luca, Lee, Jae-Lyun, Mazhar, Danish, North, Scott A., Olmos, David, Suttmann, Henrik, Zou, Qing, Li, Susan, Martin, Jason L., Park, Youn C., Sulur, Giri, Deprince, Kris, De Porre, Peter, Chi, Kim N.

“…Abstract only 182 Background: AA + P added to androgen deprivation therapy (ADT) improves overall survival (OS) in newly diagnosed mCNPC patients (pts). AA has…”
Get full text